^
    1m
    BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Luminary Therapeutics
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1m
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    2ms
    QH101 Cell Injection in Patients With Brain, Brain (Spinal) Meninges, and Spinal Cord Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=7, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    2ms
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    2ms
    ARYA3: GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Eureka Therapeutics Inc. | N=20 --> 60
    Enrollment change
    |
    GPC3 (Glypican 3)
    |
    ECT204
    2ms
    EVICTION 3: A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Not yet recruiting, Ipsen
    New P2/3 trial
    |
    Venclexta (venetoclax) • azacitidine • IPN60340
    3ms
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=115 --> 64
    Enrollment closed • Enrollment change • First-in-human
    3ms
    Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors. (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Chinese PLA General Hospital
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    3ms
    SGNEGFRd2-001: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=68, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2026 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2026; The trial was terminated for strategic reasons. The decision was not based on any safety concerns
    Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    4ms
    Clinical study of the exosome nasal spray GD002 in the treatment of Infantile Epileptic Spasms Syndrome (ChiCTR2500111373)
    P=N/A, N=36, Recruiting, The First Medical Centre, Chinese PLA General Hospital; The First Medical Centre, Chinese PLA General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=144, Recruiting, AVM Biotechnology Inc | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    dexamethasone sodium phosphate (AVM0703)
    4ms
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. (clinicaltrials.gov)
    P1, N=6, Recruiting, Tongji Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV